¼¼°èÀÇ Ä«ÅܽоïÁ¦Á¦ ½ÃÀå º¸°í¼­(2025³â)
Cathepsin Inhibitor Global Market Report 2025
»óǰÄÚµå : 1760499
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,217,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,987,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,756,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ä«ÅܽоïÁ¦Á¦ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â¿¡´Â 12¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGR 10.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº Ç¥Àû Ä¡·áÁ¦ °³¹ß, ½Å°æÅðÇ༺ Áúȯ Ä¡·á¹ý Áõ°¡, ¿¬±¸°³¹ß ÀÚ±Ý Áõ°¡, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °¨¿°¼º Áúȯ Ä¡·á¿¡ ´ëÇÑ Àû¿ë È®´ë µî¿¡ ±âÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¼±ÅÃÀû Ä«ÅܽоïÁ¦Á¦ÀÇ ºÎ»ó, »ý¸í°øÇÐ ±â¾÷ °£ Á¦ÈÞ, °æ±¸Á¦ Áß½É, AIÀÇ ½Å¾à°³¹ß Ȱ¿ë, Èñ±ÍÁúȯ Ä¡·áÁ¦·ÎÀÇ È®´ë µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.

½Å°æ ÅðÇ༺ ÁúȯÀÇ ¹ßº´·ü Áõ°¡´Â Ä«ÅܽоïÁ¦Á¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Å°æÅðÇ༺ ÁúȯÀº ÁßÃ߽Űæ°èÀÇ ½Å°æ¼¼Æ÷°¡ Á¡Â÷ÀûÀ¸·Î ÅðÈ­ ¶Ç´Â »ç¸êÇÏ´Â °ÍÀÌ Æ¯Â¡À̸ç, ƯÈ÷ ³ú¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁøÇ༺, Á¾Á¾ µ¹ÀÌų ¼ö ¾ø´Â ÁúȯÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ÀÇ Áõ°¡´Â °í·ÉÈ­ »çȸ¿Í ¹ÐÁ¢ÇÑ °ü°è°¡ ÀÖ½À´Ï´Ù. Æò±Õ ¼ö¸íÀÌ ¿¬ÀåµÊ¿¡ µû¶ó ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´°ú °°Àº Áúº´ÀÌ ´õ¿í º¸ÆíÈ­µÇ¾î ÀÇ·á ½Ã½ºÅÛ¿¡ ´õ ¸¹Àº ºÎ´ãÀ» ÁÖ°í ÀÖ½À´Ï´Ù. Ä«ÅܽоïÁ¦Á¦´Â ¾Æ¹Ð·ÎÀÌµå º£Å¸(AB) »ý¼º ¹× ½Å°æ ¿°ÁõÀ» Á¶ÀýÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ ½Å°æ ÅðÇ༺ ÁúȯÀÇ ÀáÀçÀû Ä¡·áÁ¦·Î ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Alzheimer's Association¿¡ µû¸£¸é, 2024³â 65¼¼ ÀÌ»ó ¹Ì±¹ÀÎ Áß ¾à 690¸¸ ¸íÀÌ ¾ËÃ÷ÇÏÀ̸ÓÇü Ä¡¸Å¸¦ ¾Î°í ÀÖÀ¸¸ç, 2060³â±îÁö ÀÌ ¼ýÀÚ´Â °ÅÀÇ µÎ ¹èÀÎ 1,380¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °á°úÀûÀ¸·Î ½Å°æÅðÇ༺ ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ Ä«ÅܽоïÁ¦Á¦ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

Ä«ÅܽоïÁ¦Á¦ ½ÃÀåÀÇ ±â¾÷µéÀº ½Å¾à °³¹ßÀÇ Çõ½ÅÀ» ÃËÁøÇϰí, Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϸç, ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­Çϱâ À§ÇØ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ü°áÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÆÄÆ®³Ê½ÊÀº »óÈ£º¸¿ÏÀûÀÎ Àü¹® Áö½Ä°ú ÀÚ¿øÀ» Ȱ¿ëÇÏ¿© ÀÓ»ó½ÃÇè ¹× Çã°¡ ¼º°ø·üÀ» ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 6¿ù ÀϺ» ¼ÒÀç ½Å¾à°³¹ß ±â¾÷ Alivexis´Â ½ºÀ§½º ¼ÒÀç »ý¸í°øÇÐ ±â¾÷ Melodia Therapeutics¿Í µ¶Á¡ ¶óÀ̼±½º °è¾àÀ» ü°áÇÑ ¹Ù ÀÖ½À´Ï´Ù. À̹ø °è¾àÀº AlivexisÀÇ MOD-A Ž»ö ÇÁ·Î±×·¥¿¡¼­ ¹ß±¼µÈ ½Å±Ô Ä«ÅܽŠC ¾ïÁ¦Á¦ MDI-0151ÀÇ °³¹ß, Á¦Á¶ ¹× »ó¾÷È­¿¡ ´ëÇÑ Àü ¼¼°è ±Ç¸®¸¦ ºÎ¿©ÇÏ´Â °ÍÀ¸·Î, MDI-0151Àº ANCA °ü·Ã Ç÷°ü¿°°ú °°Àº È£Áß±¸ Áß½ÉÀÇ ¿°Áõ¼º ÁúȯÀ» Ÿ°ÙÀ¸·Î ÇÕ´Ï´Ù. Melodia´Â ÀÓ»óÀû °³³äÁõ¸íÀ» È®¸³Çϱâ À§ÇÑ 1/2a»ó ½ÃÇèÀ» À§ÇØ IND ȹµæÀ» À§ÇÑ È°µ¿À» ½ÃÀÛÇÒ ¿¹Á¤ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Cathepsin inhibitors are compounds that block the activity of cathepsins, enzymes involved in various biological processes such as protein degradation and cell regulation. These inhibitors are being studied for their potential to treat diseases by modulating cathepsin activity. Their ability to target specific biological mechanisms positions them as promising candidates for therapeutic development.

The main types of cathepsin inhibitors include small molecule inhibitors, peptide inhibitors, and monoclonal antibodies. Small molecule cathepsin inhibitors are low molecular weight compounds specifically designed to block the activity of cathepsin enzymes. These inhibitors are applied in the treatment of cancer, autoimmune diseases, inflammatory disorders, neurodegenerative conditions, and other therapeutic areas. Distribution channels for these products include online pharmacies, retail pharmacies, and hospitals and clinics, serving end users such as pharmaceutical companies, academic and research institutions, and contract research organizations (CROs).

The cathepsin inhibitor market research report is one of a series of new reports from The Business Research Company that provides cathepsin inhibitor market statistics, including cathepsin inhibitor industry global market size, regional shares, competitors with a cathepsin inhibitor market share, detailed cathepsin inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the cathepsin inhibitor industry. This cathepsin inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cathepsin inhibitor market size has grown rapidly in recent years. It will grow from$0.76 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth during the historic period can be attributed to the rising incidence of cancer, the increasing prevalence of inflammatory diseases, growing investments in drug discovery, advancements in protease research, and the expanding use of cathepsin inhibitors in treating bone disorders.

The cathepsin inhibitor market size is expected to see rapid growth in the next few years. It will grow to$1.26 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to the development of targeted therapies, the rise in treatments for neurodegenerative diseases, increased funding for research and development, growing demand for precision medicine, and expanding applications in infectious disease treatment. Key trends during this period include the emergence of selective cathepsin inhibitors, collaborations between biotech firms, a focus on oral drug formulations, the use of AI in drug discovery, and the expansion into therapeutics for rare diseases.

The growing incidence of neurodegenerative disorders is expected to fuel the expansion of the cathepsin inhibitor market. Neurodegenerative disorders are progressive, often irreversible conditions characterized by the gradual deterioration or death of neurons in the central nervous system, particularly impacting the brain. The rise in these disorders is closely linked to the aging population. As life expectancy increases, conditions such as Alzheimer's and Parkinson's become more common, adding further strain to healthcare systems. Cathepsin inhibitors are being studied as potential therapeutic agents for neurodegenerative diseases due to their ability to modulate amyloid-beta (AB) production and neuroinflammation. For example, according to the Alzheimer's Association, in 2024, about 6.9 million Americans aged 65 and older are living with Alzheimer's dementia, and this number is expected to nearly double to 13.8 million by 2060. As a result, the increasing prevalence of neurodegenerative disorders is driving the demand for cathepsin inhibitors.

Companies in the cathepsin inhibitor market are forming strategic partnerships to drive innovation in drug discovery, expand their product portfolios, and speed up market entry. These collaborations aim to leverage complementary expertise and resources to enhance the success rates of clinical trials and regulatory approvals. For example, in June 2024, Alivexis, a Japan-based drug discovery company, entered into an exclusive licensing agreement with Melodia Therapeutics, a Switzerland-based biotech firm. The agreement grants worldwide rights to the development, manufacturing, and commercialization of MDI-0151, a novel cathepsin C inhibitor. MDI-0151, identified in Alivexis' MOD-A discovery program, is targeted at neutrophil-driven inflammatory diseases such as ANCA-associated vasculitis. Melodia plans to initiate IND-enabling activities in preparation for Phase 1/2a studies to establish clinical proof of concept.

In April 2022, AddLife AB, a Swedish life science company, acquired BioCat GmbH for an undisclosed amount. This acquisition was aimed at strengthening AddLife's presence in the DACH (Germany, Austria, and Switzerland) region and expanding its Labtech business area through increased collaboration with its existing European subsidiaries. BioCat GmbH, a Germany-based life sciences company, specializes in providing cathepsin K inhibitors for use in biological research and drug development.

Major players in the cathepsin inhibitor market are Merck KGaA, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Bio-Techne Corporation, AddLife AB, BioVision, R&D Systems Inc., Cayman Chemical, Selleck Chemicals, Santa Cruz Animal Health, Tocris Bioscience, Virobay Inc., MedChemExpress, BOC Sciences, Biorbyt Ltd, GlpBio Technology, Echelon Biosciences, AG Scientific, ApexBio Technology, and OXiGENE Inc.

North America was the largest region in the cathepsin Inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cathepsin inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cathepsin inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cathepsin inhibitor market consists of sales of small-molecule inhibitors, prescription drugs, research-grade inhibitors, and therapeutic formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cathepsin Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cathepsin inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cathepsin inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cathepsin inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Cathepsin Inhibitor Market Characteristics

3. Cathepsin Inhibitor Market Trends And Strategies

4. Cathepsin Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cathepsin Inhibitor Growth Analysis And Strategic Analysis Framework

6. Cathepsin Inhibitor Market Segmentation

7. Cathepsin Inhibitor Market Regional And Country Analysis

8. Asia-Pacific Cathepsin Inhibitor Market

9. China Cathepsin Inhibitor Market

10. India Cathepsin Inhibitor Market

11. Japan Cathepsin Inhibitor Market

12. Australia Cathepsin Inhibitor Market

13. Indonesia Cathepsin Inhibitor Market

14. South Korea Cathepsin Inhibitor Market

15. Western Europe Cathepsin Inhibitor Market

16. UK Cathepsin Inhibitor Market

17. Germany Cathepsin Inhibitor Market

18. France Cathepsin Inhibitor Market

19. Italy Cathepsin Inhibitor Market

20. Spain Cathepsin Inhibitor Market

21. Eastern Europe Cathepsin Inhibitor Market

22. Russia Cathepsin Inhibitor Market

23. North America Cathepsin Inhibitor Market

24. USA Cathepsin Inhibitor Market

25. Canada Cathepsin Inhibitor Market

26. South America Cathepsin Inhibitor Market

27. Brazil Cathepsin Inhibitor Market

28. Middle East Cathepsin Inhibitor Market

29. Africa Cathepsin Inhibitor Market

30. Cathepsin Inhibitor Market Competitive Landscape And Company Profiles

31. Cathepsin Inhibitor Market Other Major And Innovative Companies

32. Global Cathepsin Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cathepsin Inhibitor Market

34. Recent Developments In The Cathepsin Inhibitor Market

35. Cathepsin Inhibitor Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â